J Cardiovasc Med (Hagerstown) 2021 Apr 28. Epub 2021 Apr 28.
Department of Cardiovascular Diseases - AUSL Romagna, Division of Cardiology, S. Maria delle Croci Hospital, Ravenna Department of Cardiothoracic Sciences, Division of Cardiology, S. Maria della Misericordia Hospital, Udine Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, S. Maria della Misericordia Hospital, Perugia Institute of Pharmacology, Catholic University School of Medicine, Rome Department of Cardiovascular Diseases, Division of Cardiology, Fondazione Poliambulanza, Brescia Division of Emergency Medicine and Surgery, S. Anna and S. Sebastiano Hospital, Caserta Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
Aim: To evaluate the current interpretation of the lower doses of direct oral anticoagulants (DOAC) dabigatran, apixaban, edoxaban and rivaroxaban in nonvalvular atrial fibrillation.
Methods: A questionnaire of 14 statements to which the possible answers were fully agree/partially agree/partially disagree/fully disagree or yes/no was prepared within the board of the Italian Atherosclerosis, Thrombosis and Vascular Biology Study Group and forwarded to individual Italian physicians.
Results: A total of 620 complete questionnaires were received from nearly all the Italian regions and physicians of various medical specialists, either enabled or not for the prescription of DOAC. Read More